Institution
Bayer (Greece)
Recent research
- Health & MedicineOpen access
Elinzanetant for menopause-associated sleep disturbance: pooled analysis of two phase III studies
Objective This study aimed to evaluate the effects of elinzanetant on sleep in postmenopausal women with vasomotor symptoms (VMS), including by symptom burden.Method Pooled phase III OASIS-1 and OASIS-2 data included postmenopausal women aged 40–65 years experiencing ≥50 moderate...
- Health & MedicineOpen access
Elinzanetant for menopause-associated vasomotor symptoms: pooled analysis of two phase III trials
Objective This study aimed to evaluate the vasomotor symptoms (VMS) efficacy profile of elinzanetant (dual neurokinin-1 and neurokinin-3 receptor antagonist).Method Data were pooled from the phase III 26-week (12-week placebo-controlled) OASIS-1 and OASIS-2 trials, enrolling natu...